Ipilimumab treatment has been associated with severe and potentially fatal immunological adverse effects due to [[T cell activation]] and proliferation; these occur in 10-20% of people and are a major drawback of this drug.<ref name=2015TherAdvRev>{{cite journal |vauthors=Johnson DB, Peng C, Sosman JA |title=Nivolumab in melanoma: latest evidence and clinical potential |journal=Ther Adv Med Oncol |volume=7 |issue=2 |pages=97–106 |year=2015 |pmid=25755682 |pmc=4346215 |doi=10.1177/1758834014567469 |url=}}</ref>  Most of the serious adverse effects are associated with the [[gastro-intestinal tract]]; they include stomach pain, bloating, constipation or diarrhea, but also fever, breathing or urinating problems. A "risk evaluation and mitigation strategy" informs prescribers of the potential risks.<ref name="Drugs.com">Drugs.com: [http://www.drugs.com/yervoy.html Yervoy]</ref><ref>{{cite web | url = http://www.genengnews.com/gen-news-highlights/fda-rubber-stamps-bristol-myers-squibb-s-melanoma-mab/81244882/ | title = FDA Rubber-Stamps Bristol-Myers Squibb’s Melanoma mAb | date = 2011-03-28 | publisher =  Genetic Engineering & Biotechnology News | accessdate =  2011-03-28 }}</ref> {{expand section|date=March 2016}} <!-- what rates of incidence -->

 


 
Individual cases of severe neurologic disorders following ipilimumab have been observed, including acute inflammatory [[demyelination]] [[polyneuropathy]] and an ascending [[motor paralysis]], and [[myasthenia gravis]].<ref>{{cite web | url = http://www.medscape.com/viewarticle/824347 | title = Two Cases of Myasthenia Gravis Seen With Ipilimumab | date = 2014-04-29 }}</ref>

 

